Adherium’s Smartinhaler platform to be used by Astrazeneca for US COPD study
Melbourne, Australia, 13 June 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub- optimal medication use in chronic disease, today announced that AstraZeneca will use Adherium’s Smartinhaler™ platform in an important new US clinical study that aims to improve medication adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
The study will be conducted at seven US healthcare centres, and enroll nearly 400 COPD patients, starting in August. The study will end after 12 months.
“This study is important research because adherence rates in COPD patients are low, and Adherium’s Smartinhaler™ is the gold standard in recording and improving medication adherence in chronic lung disease. Adherium is supplying the technology platform for this study under the long term Master Supply and Development Agreement already entered into with AstraZeneca,” said Adherium’s Group CEO Garth Sutherland.
The SmartTouch™ Symbicort® device that will be used in this study features a modernized industrial design, miniaturization of electronic sensors, and improved usability, each showcasing the investment Adherium has made in its technology since listing on the Australian Securities Exchange in August 2015.